title: Relationship between amount of beta-blockers permeating through the stratum corneum and skin irritation after application of beta-blocker adhesive patches to guinea pig skin.
abstract: We evaluated the relationship between the cumulative amounts of 5 kinds of beta-blockers (alprenolol, oxprenolol, timolol, acebutolol and atenolol) permeating through the stratum corneum and a* values obtained by measuring the formation of erythema, a skin irritation reaction, with a chromameter after transdermal application of adhesive patches containing 2 beta-blocker to the skin of guinea pigs. The cumulative amount of beta-blocker released from each adhesive patch to the skin increased with the increase in application time. The contents of alprenolol, oxprenolol and timolol in the stratum corneum and in the stripped skin increased markedly up to 4 h after application and thereafter were maintained at high levels up to 24 h. The contents of acebutolol and atenolol, on the other hand, increased up to 24 h, but these values were low. a* values of all adhesive patches 24 h after application were higher than those before application. The correlation coefficients between the cumulative amounts of alprenolol, oxprenolol, timolol, acebutolol or atenolol permeating through the stratum corneum and (delta a* -delta a*Placebo) values were 0.739, 0.717, 0.722, 0.551 and 0.633, respectively. The correlation coefficient calculated by averaging the cumulative amounts of 6 kinds of beta-blockers permeating through the stratum corneum [including propranolol which was reported previously (Kobayashi I., et al., Biol. Pharm. Bull., 19, 839-844 (1996))] was 0.731, higher than the correlation coefficient between contents of these beta-blockers in the stripped skin and (delta a* -delta a*Placebo) values (r = 0.552). This suggests that there was a high correlation between the cumulative amounts of beta-blockers permeating through the stratum corneum and (delta a* -delta a*Placebo) values.
authors.affiliation: Toxicological Research Center, Nitto Denko Corporation, Osaka, Japan.
authors.forename: I
authors.initials: I
authors.lastname: Kobayashi
authors.forename: K
authors.initials: K
authors.lastname: Hosaka
authors.forename: T
authors.initials: T
authors.lastname: Ueno
authors.forename: H
authors.initials: H
authors.lastname: Maruo
authors.forename: M
authors.initials: M
authors.lastname: Kamiyama
authors.forename: C
authors.initials: C
authors.lastname: Konno
authors.forename: M
authors.initials: M
authors.lastname: Gemba
mesh_terms: D000070:Acebutolol / Q000008:administration & dosage / Q000378:metabolism / Q000633:toxicity; D000279:Administration, Cutaneous; D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000378:metabolism* / Q000633:toxicity; D000526:Alprenolol / Q000008:administration & dosage / Q000378:metabolism / Q000633:toxicity; D000818:Animals; D001262:Atenolol / Q000008:administration & dosage / Q000378:metabolism / Q000633:toxicity; D017453:Dermatitis, Irritant / Q000209:etiology* / Q000378:metabolism; D006168:Guinea Pigs; D008297:Male; D010096:Oxprenolol / Q000008:administration & dosage / Q000378:metabolism / Q000633:toxicity; D012867:Skin / Q000187:drug effects / Q000378:metabolism*; D012869:Skin Absorption; D013999:Timolol / Q000008:administration & dosage / Q000378:metabolism / Q000633:toxicity
chemical_list: D000319:Adrenergic beta-Antagonists; D001262:Atenolol; D010096:Oxprenolol; D000070:Acebutolol; D013999:Timolol; D000526:Alprenolol